SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934 (Amendment No. 8)*
BioTime, Inc.
.................................................................................
(Name of Issuer)
Common Shares, no par value
.................................................................................
(Title of Class of Securities)
09066L105
.................................................................................
(CUSIP Number)
Paul Segall and Judith Segall
935 Pardee Street, Berkeley, California 94710; (510) 845-9535
.................................................................................
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
April 17, 2002
.................................................................................
(Date of Event which Requires Filing this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of ss.ss.240.13d-1(e), 240.13d-1(f), or 240.13d-1(g), check the
following box [ ].
NOTE: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See ss.240.13d-7(b) for other
parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
CUSIP No. 09066L105
1) Names of Reporting Persons S.S. or I.R.S. Identification Nos. of
Above Persons
Paul Segall
2) Check the Appropriate Box if a Member of a Group (See
Instructions) (a) [ ]
(b) [ ]
3) SEC Use Only
4) Source of Funds (See Instructions)
PF; OO
5) Check if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e) [ ]
6) Citizenship or Place of Organization
U.S.A.
7) Sole Voting Power
Number of 343,245
Shares
Beneficially 8) Shared Voting Power
Owned by 0
Each
Reporting 9) Sole Dispositive Power
Person With 343,245
10) Shared Dispositive Power
0
11) Aggregate Amount Beneficially Owned by Each Reporting Person
545,408
12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions) [ ]
13) Percent of Class Represented by Amount in Row (11)
4.69%
14) Type of Reporting Person (See Instructions)
IN
Page 2 of 4 Pages
CUSIP No. 09066L105
1) Names of Reporting Persons S.S. or I.R.S. Identification Nos. of
Above Persons
Judith Segall
2) Check the Appropriate Box if a Member of a Group (See
Instructions) (a) [ ]
(b) [ ]
3) SEC Use Only
4) Source of Funds (See Instructions)
PF; OO
5) Check if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e) [ ]
6) Citizenship or Place of Organization
U.S.A.
7) Sole Voting Power
Number of 202,163
Shares
Beneficially 8) Shared Voting Power
Owned by 0
Each
Reporting 9) Sole Dispositive Power
Person With 202,163
10) Shared Dispositive Power
0
11) Aggregate Amount Beneficially Owned by Each Reporting Person
545,408
12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions) [ ]
13) Percent of Class Represented by Amount in Row (11)
4.69%
14) Type of Reporting Person (See Instructions)
IN
Page 3 of 4 Pages
Item 1. Security and Issuer
The class of equity securities to which this schedule relates is Common
Shares, no par value (the "Common Shares"), of BioTime, Inc., a California
corporation (the "Company"). The Company has its principal executive offices at
935 Pardee Street, Berkeley, California 94710.
This schedule is being filed pursuant to Section 13(d) of the Securities
Exchange Act of 1934, as amended (the "Exchange Act") and the rules and
regulations promulgated thereunder.
Item 4. Interest in Securities of the Issuer
In order to reduce the amount of his margin indebtedness, on April 17, 2002
Paul Segall sold 100,000 Common Shares to Alfred D. Kingsley for $2.50 per
share, in a privately negotiated transaction. Paul Segall now directly owns
343,245 Common Shares, which constitute approximately 2.95% of the 11,627,316
Common Shares outstanding on March 7, 2002. Judith Segall directly owns 202,163
Common Shares, which constitute approximately 1.7% of the 11,627,316 Common
Shares outstanding on March 7, 2002. The Common Shares owned by Mr. and Mrs.
Segall in the aggregate constitute approximately 4.69% of the 11,627,316 Common
Shares outstanding on March 7, 2002. The forgoing number of outstanding Common
Shares is based upon information provided by the Company in its Annual Report on
Form 10-K for the year ending December 31, 2001, as filed with the Securities
and Exchange Commission.
Signature
After reasonable inquiry and to the best of our knowledge we certify that
the information set forth in the statement is true, complete and correct.
Dated: April 18, 2002 /s/ Paul Segall
---------------------------------------
Paul Segall
Dated: April 18, 2002 /s/ Judith Segall
---------------------------------------
Judith Segall
Page 4 of 4 Pages